A new compound, discovered jointly by international pharmaceutical company Servier, headquartered in France, and Vernalis (R&D), a company based in the UK, has been shown by researchers at the Walter and Eliza Hall Institute and Servier to block a protein that is essential for the sustained growth of up to a quarter of all cancers.
The research presents a new way to efficiently kill these cancerous cells and holds promise for the treatment of blood cancers such as acute myeloid leukaemia,lymphoma and multiple myeloma, as well as solid cancers such as melanoma and cancers of the lung and breast. It is published online today in the journal Nature.
The Servier compound – S63845 – targets a protein of the BCL2 family, called MCL1, which is essential for the sustained survival of these cancer cells.
Institute scientist Associate Professor Guillaume Lessene, who led the Walter and Eliza Hall Institute’s research team in Melbourne, Australia, said the work provided the first clear preclinical evidence that inhibiting MCL1 was effective in targeting several cancer types.
“MCL1 is important for many cancers because it is a pro-survival protein that allows the cancerous cells to evade the process of programmed cell death that normally removes cancer cells from the body,” Associate Professor Lessene said. “Extensive studies performed in a variety of cancer models have shown that S63845 potently targets cancer cells dependent on MCL1 for their survival.”
The institute team of Associate Professor Lessene worked with haematologist Associate Professor Andrew Wei and Dr Donia Moujalled from The Alfred Hospital and Servier scientists, to demonstrate that not only was S63845 effective against several cancer types, but that it could also be delivered at doses that were well tolerated by normal cells.
Dr Olivier Geneste, Director of Oncology Research at Servier, said this preclinical research represented major findings regarding the druggability of MCL1, a valuable and highly challenging target. “S63845 was discovered through collaboration with the fragment and structure based discovery expertise at Vernalis,” he said. “As part of the ongoing Servier / Novartis collaboration on this target class, clinical development of a MCL1 inhibitor should be launched in the near future.”
Associate Professor Lessene said the research provided further evidence of the usefulness of a new class of anti-cancer drugs called BH3 mimetics. “BH3 mimetics inhibit a group of proteins known as the ‘pro-survival BCL-2 proteins’,” he said. “MCL1 is a member of this protein family, and inhibiting it activates the process of programmed cell death. Walter and Eliza Hall Institute researchers revealed the role of BCL-2 in cancer more than 28 years ago and the essential role of MCL1 for the survival of malignant cells four years ago.”
The Latest on: Cancer treatment
via Google News
The Latest on: Cancer treatment
- Know the risks of prostate canceron September 26, 2021 at 9:10 pm
Prostate cancer is an ugly term to American men. That’s because the disease is the most frequently diagnosed cancer in men, and it’s the second leading cause of cancer deaths in men, trailing only ...
- Nottinghamshire hospitals failed to meet treatment target with half of breast cancer patientson September 26, 2021 at 8:00 pm
Hospitals in Nottinghamshire are failing to refer half of breast cancer patients for treatment within the targeted time. In July, Sherwood Forest Hospitals referred just over 50% of breast cancer ...
- Blood Cancer Awareness Month: What Are The Different Types and Treatments Available?on September 25, 2021 at 11:42 pm
In the month of September every year, we celebrate blood cancer awareness month. There are types of blood cancer which include hematologic cancers that start in the bone marrow, which is where blood ...
- Life-saving cancer treatment being ‘rationed’ as NHS struggles with staff shortageson September 24, 2021 at 3:10 pm
PATIENTS with advanced or terminal cancer are reportedly being denied life-extending treatment because of a staff shortage. One of England’s largest trusts has admitted rationing is taking ...
- For Men with Prostate Cancer, When Is Active Surveillance Better than Treatment?on September 24, 2021 at 2:10 pm
Learn why Bobby Logan chose active surveillance for his prostate cancer, and how he was successfully treated after his tumor changed.
- New 3D pancreatic cancer model could be used to develop and test targeted treatmentson September 24, 2021 at 6:01 am
An international team of scientists have created a three-dimensional (3D) pancreatic cancer tumour model in the laboratory, combining a bioengineered matrix and patient-derived cells that could be ...
- Lab Grown 3D Tumor Models Could Improve Treatment for Pancreatic Canceron September 24, 2021 at 2:00 am
An international team of scientists has created a three-dimensional (3D) pancreatic cancer tumor model in the laboratory, combining a bioengineered matrix and patient-derived cells that could be used ...
- Family of Boy, 11, with Cancer Pleads for Help to Raise $500K for Treatment: 'His Last Chance'on September 23, 2021 at 12:20 pm
The family of a young boy battling stage 4 cancer is pleading for help to fund an experimental — and possibly life-saving — treatment for him as time runs out. Kian Faghih was diagnosed with alveolar ...
- Metastatic prostate cancer comes in two forms, which could guide treatmenton September 23, 2021 at 8:00 am
Scientists have identified two subtypes of metastatic prostate cancer that respond differently to treatment, information that could one day guide physicians in treating patients with the therapies ...
via Bing News